Probing the anticancer activities of facial trioxorhenium and tricarbonylrhenium compounds with heterocyclic ligands

Candace Davison,Shabaaz Abdullah,Christie Jane Smit,Phakamani Dlamini,Irvin Noel Booysen,Jo-Anne de la Mare
DOI: https://doi.org/10.1016/j.cbi.2024.111351
IF: 5.168
2024-12-16
Chemico-Biological Interactions
Abstract:The cytotoxicity of four rhenium compounds: fac -[ReO 3 (impy)CH 3 ] ( 1 ) (impy = 2-(1 H -imidazol-2-yl)pyridine), fac -[Re(CO) 3 (bzimpy)Cl] ( 2 ) (bzimpy = 2-(2-pyridyl)benzimidazole), fac -[Re(CO) 3 (bibzimpy)Cl] ( 3 ) (bibzimpy = 2,6- bis (2-benzimidazolyl)pyridine) and fac -[Re(CO) 3 (impy)Cl] ( 4 ) was assessed against cancer cell lines, namely, the cervical hormone-responsive HeLa and the triple-negative breast cancer (TNBC) HCC70 lines versus a non-tumorigenic control breast epithelial cell line, MCF12A. A rare facial trioxorhenium(VII) compound 1 was characterized via various physicochemical techniques. The rhenium compounds 1 - 4 were, in general, more cytotoxic to HeLa cells, compared to the TNBC HCC70 line, displaying half maximal inhibitory concentration (IC 50 ) values in the micromolar range, however, the compounds were not convincingly selective for cancer cells over non-cancerous cells. In particular, compound 4 was highly cytotoxic towards HCC70, HeLa, and MCF12A cells, displaying low micromolar toxicity with IC 50 values of 6.57 ± 1.11 μM, 8.88 ± 1.07 and 9.41 ± 1.04 μM in these three cell lines, respectively and was selected for further study as it displayed the greatest cytotoxicity against the highly treatment-resistant HCC70 TNBC cell line. Compound 4 was able to both bind to genomic DNA and act as an intercalator of CT-DNA, however, this did not lead to DNA damage as assessed by a comet assay. In addition, Compound 4 displayed a long-term dose-dependent effect on colony formation and long-term survival as a proxy of in vivo toxicity.
pharmacology & pharmacy,biochemistry & molecular biology,toxicology
What problem does this paper attempt to address?